318 related articles for article (PubMed ID: 22122056)
21. Gamma-secretase inhibitors and Alzheimer's disease.
Roberts SB
Adv Drug Deliv Rev; 2002 Dec; 54(12):1579-88. PubMed ID: 12453675
[TBL] [Abstract][Full Text] [Related]
22. [Targeting the structure and function relationships of the gamma-secretase for the development of Alzheimer's disease].
Tomita T
Rinsho Shinkeigaku; 2008 Nov; 48(11):907-9. PubMed ID: 19198114
[TBL] [Abstract][Full Text] [Related]
23. gamma-Secretase modulators.
Wolfe MS
Curr Alzheimer Res; 2007 Dec; 4(5):571-3. PubMed ID: 18220525
[TBL] [Abstract][Full Text] [Related]
24. The inhibition of gamma-secretase as a therapeutic approach to Alzheimer's disease.
Tomita T; Iwatsubo T
Drug News Perspect; 2004 Jun; 17(5):321-5. PubMed ID: 15334182
[TBL] [Abstract][Full Text] [Related]
25. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
26. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
27. Developing β-secretase inhibitors for treatment of Alzheimer's disease.
Ghosh AK; Brindisi M; Tang J
J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):71-83. PubMed ID: 22122681
[TBL] [Abstract][Full Text] [Related]
28. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
[TBL] [Abstract][Full Text] [Related]
29. Role of γ-Secretase Inhibitors for the Treatment of Diverse Disease Conditions through Inhibition of Notch Signaling Pathway.
Mondal A; Bose S; Banerjee S; Pal D
Curr Drug Targets; 2021; 22(15):1799-1807. PubMed ID: 33992061
[TBL] [Abstract][Full Text] [Related]
30. The presenilins in Alzheimer's disease--proteolysis holds the key.
Haass C; De Strooper B
Science; 1999 Oct; 286(5441):916-9. PubMed ID: 10542139
[TBL] [Abstract][Full Text] [Related]
31. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
32. APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.
Wolfe MS
Int Immunopharmacol; 2002 Dec; 2(13-14):1919-29. PubMed ID: 12489805
[TBL] [Abstract][Full Text] [Related]
33. Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1.
Raven F; Ward JF; Zoltowska KM; Wan Y; Bylykbashi E; Miller SJ; Shen X; Choi SH; Rynearson KD; Berezovska O; Wagner SL; Tanzi RE; Zhang C
EBioMedicine; 2017 Oct; 24():93-101. PubMed ID: 28919280
[TBL] [Abstract][Full Text] [Related]
34. Gamma-secretase inhibition and modulation for Alzheimer's disease.
Wolfe MS
Curr Alzheimer Res; 2008 Apr; 5(2):158-64. PubMed ID: 18393800
[TBL] [Abstract][Full Text] [Related]
35. Intramembrane proteolysis by gamma-secretase.
Steiner H; Fluhrer R; Haass C
J Biol Chem; 2008 Oct; 283(44):29627-31. PubMed ID: 18650432
[TBL] [Abstract][Full Text] [Related]
36. [Alzheimer's disease treatment by inhibition/modulation of the gamma-secretase activity].
Tomita T
Rinsho Shinkeigaku; 2009 Nov; 49(11):845-7. PubMed ID: 20030227
[TBL] [Abstract][Full Text] [Related]
37. Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics.
Patey SJ; Edwards EA; Yates EA; Turnbull JE
Neurodegener Dis; 2008; 5(3-4):197-9. PubMed ID: 18322389
[TBL] [Abstract][Full Text] [Related]
38. [Development of Alzheimer's disease treatment based on the molecular mechanism of γ-secretase activity].
Tomita T
Rinsho Shinkeigaku; 2012; 52(11):1165-7. PubMed ID: 23196551
[TBL] [Abstract][Full Text] [Related]
39. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
[TBL] [Abstract][Full Text] [Related]
40. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
Imbimbo BP; Giardina GA
Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
